高剂量促红细胞生成素减少极早产儿输血需求的随机临床试验事后分析
该事后分析基于PENUT随机双盲试验,纳入936例胎龄24至27周的极早产儿,比较出生24小时内至纠正胎龄32周给予高剂量促红细胞生成素与安慰剂的输血需求。结果显示促红细胞生成素组输血次数、累计输血量和供者暴露均低于安慰剂组,且更多患儿在生后12周内未接受输血。
要点
- 高剂量促红细胞生成素可减少极早产儿输血次数、累计输血量和供者暴露。
- 促红细胞生成素组在纠正胎龄33周时血细胞比容 tended 更高。
- 生后12周内未输血比例促红细胞生成素组高于安慰剂组。
核心结论
- 按PENUT方案使用高剂量促红细胞生成素可有效减少极早产儿的输血需求。
研究设计与样本
- PENUT为随机双盲临床试验,在美国19个中心30个新生儿重症监护病房开展。
- 筛查3266例,排除2325例,纳入941例随机分配至促红细胞生成素组477例或安慰剂组464例。
- 纳入胎龄24周0-6天至27周6-7天,排除已知影响神经发育结局的疾病。
- 事后分析纳入936例,平均胎龄25.6周(SD 1.2),平均出生体重799 g(SD 189)。
主要发现
- 促红细胞生成素组与安慰剂组未调整平均输血次数分别为3.5次(SD 4.0)与5.2次(SD 4.4),相对率0.66(95% CI 0.59-0.75)。
- 促红细胞生成素组与安慰剂组平均累计输血量分别为47.6 mL(SD 60.4)与76.3 mL(SD 68.2),平均差-25.7 mL(95% CI 18.1-33.3)。
- 促红细胞生成素组与安慰剂组平均供者暴露分别为1.6(SD 1.7)与2.4(SD 2.0),相对率0.67(95% CI 0.58-0.77)。
- 胎龄27周患儿在纠正胎龄33周时,促红细胞生成素组与安慰剂组平均血细胞比容分别为36.9%(SD 5.5%)与30.4%(SD 4.6%),P < .001。
- 936例中160例(17.1%)在生后12周结束时未输血,其中安慰剂组43例、促红细胞生成素组117例(P < .001)。
关键数值与推荐
- 促红细胞生成素1000 U/kg或安慰剂每48小时一次共6剂,随后400 U/kg或假注射每周3次至纠正胎龄32周。
临床怎么用
- 对于胎龄24至27周的极早产儿,可考虑按PENUT方案使用高剂量促红细胞生成素以减少输血次数、累计输血量和供者暴露。
局限性
- 本文为事后分析,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Extremely preterm infants are among the populations receiving the highest levels of transfusions. Erythropoietin has not been recommended for premature infants because most studies have not demonstrated a decrease in donor exposure. OBJECTIVES: To determine whether high-dose erythropoietin given within 24 hours of birth through postmenstrual age of 32 completed weeks will decrease the need for blood transfusions. DESIGN, SETTING, AND PARTICIPANTS: The Preterm Erythropoietin Neuroprotection Trial (PENUT) is a randomized, double-masked clinical trial with participants enrolled at 19 sites consisting of 30 neonatal intensive care units across the United States. Participants were born at a gestational age of 24 weeks (0-6 days) to 27 weeks (6-7 days). Exclusion criteria included conditions known to affect neurodevelopmental outcomes. Of 3266 patients screened, 2325 were excluded, and 941 were enrolled and randomized to erythropoietin (n = 477) or placebo (n = 464). Data were collected from December 12, 2013, to February 25, 2019, and analyzed from March 1 to June 15, 2019. INTERVENTIONS: In this post hoc analysis, erythropoietin, 1000 U/kg, or placebo was given every 48 hours for 6 doses, followed by 400 U/kg or sham injections 3 times a week through postmenstrual age of 32 weeks. MAIN OUTCOMES AND MEASURES: Need for transfusion, transfusion numbers and volume, number of donor exposures, and lowest daily hematocrit level are presented herein. RESULTS: A total of 936 patients (488 male [52.1%]) were included in the analysis, with a mean (SD) gestational age of 25.6 (1.2) weeks and mean (SD) birth weight of 799 (189) g. Erythropoietin treatment (vs placebo) decreased the number of transfusions (unadjusted mean [SD], 3.5 [4.0] vs 5.2 [4.4]), with a relative rate (RR) of 0.66 (95% CI, 0.59-0.75); the cumulative transfused volume (mean [SD], 47.6 [60.4] vs 76.3 [68.2] mL), with a mean difference of -25.7 (95% CI, 18.1-33.3) mL; and donor exposure (mean [SD], 1.6 [1.7] vs 2.4 [2.0]), with an RR of 0.67 (95% CI, 0.58-0.77). Despite fewer transfusions, erythropoietin-treated infants tended to have higher hematocrit levels than placebo-treated infants, most noticeable at gestational week 33 in infants with a gestational age of 27 weeks (mean [SD] hematocrit level in erythropoietin-treated vs placebo-treated cohorts, 36.9% [5.5%] vs 30.4% [4.6%] (P < .001). Of 936 infants, 160 (17.1%) remained transfusion free at the end of 12 postnatal weeks, including 43 in the placebo group and 117 in the erythropoietin group (P < .001). CONCLUSIONS AND RELEVANCE: These findings suggest that high-dose erythropoietin as used in the PENUT protocol was effective in reducing transfusion needs in this population of extremely preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01378273.
引用
- Juul SE, Vu PT, Comstock BA, et al. Effect of High-Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2020. PMID: 32804205. doi:10.1001/jamapediatrics.2020.2271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。